The Effect of Increasing Dietary Protein on the Gut Microbiome and Its Metabolites
PSGM
1 other identifier
interventional
87
1 country
1
Brief Summary
This study will determine the effect of dietary protein not absorbed in the small intestine on the bacteria in the large intestine and the metabolites those bacteria produce when they break down the protein. The three specific goals are:
- 1.Determine if increasing dietary protein increases the purine breakdown product, allantoin, as observed in our previous study.
- 2.Establish a model to examine the effect of dietary protein on the gut microbiota and metabolites.
- 3.Identify gut bacteria and metabolite changes that occur with increased consumption of animal (whey) or plant (pea) protein sources.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2023
CompletedFirst Submitted
Initial submission to the registry
November 4, 2024
CompletedFirst Posted
Study publicly available on registry
November 6, 2024
CompletedNovember 6, 2024
September 1, 2024
10 months
November 4, 2024
November 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fecal allantoin
A cross-sectional study the investigators conducted found that healthy individuals who reported consuming, on average, 150 gms of protein daily had a higher fecal allantoin. This study is a pre/post-randomized controlled trial to confirm that observation. It will determine if consuming 50 gms more protein daily increases fecal allantoin.
A fecal sample is collected before and after consuming a protein supplement (pea or whey) for seven days.
Secondary Outcomes (2)
Changes in fecal bacterial species before and after increasing dietary protein intake (pea or whey) by 50 grams for seven days
A fecal sample is collected before and after consuming a protein supplement (pea or whey) for seven days.
Changes in fecal metabolites before and after increasing dietary protein intake (pea or whey) by 50 grams for seven days
A fecal sample is collected before and after consuming a protein supplement (pea or whey) for seven days.
Study Arms (2)
Whey protein supplement
EXPERIMENTALThis group of participants will consume 50 g of whey protein supplement daily.
Pea protein supplement
EXPERIMENTALThis group of participants will consume 50 g of pea protein supplement daily.
Interventions
This intervention will add 50 g of a whey or pea protein supplement to their usual dietary intake.
This intervention will add 50 g of a pea protein supplement to their usual dietary intake.
Eligibility Criteria
You may qualify if:
- years old or older
- male or female
- located in the contiguous United States
You may not qualify if:
- Taken any prebiotics in the last week
- Taken any probiotics in the last week
- Taken any prescription medications other than oral contraceptives
- Taken antibiotics sometime in the last three months
- Taken any diarrhea inhibitors in the last week
- Taken any laxatives in the last week
- Taken any dietary supplement(s)
- Diagnosed with cancer
- Diagnosed with an inflammatory disease of the GI tract, such as irritable bowel disease
- Experienced long-haul COVID fatigue
- Were physically inactive (\<600 METS per week)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Louisiana State University Health Sciences Center New Orleans
New Orleans, Louisiana, 70112, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lauri O. Byerley, PhD
APUS/LSUHSC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 4, 2024
First Posted
November 6, 2024
Study Start
February 1, 2023
Primary Completion
November 30, 2023
Study Completion
November 30, 2023
Last Updated
November 6, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- Data requests can be submitted six months after article publication and will be accessible for up to 24 months.
- Access Criteria
- Qualified researchers engaged in independent scientific research can request access to this study's IPD, which will be provided following the review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). D
Data requests can be submitted six months after article publication. Qualified researchers engaged in independent scientific research can request access to this study's IPD, which will be provided following the review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis. For more information or to submit a request, please contact lbyerl@lsuhsc.edu.